ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M

Novacap Acquires PCI Synthesis

June 28, 2018

Pharmaceuticals

Novacap has completed the acquisition of PCI Synthesis, a U.S.-based small-molecule CDMO with R&D and manufacturing sites in Massachusetts. The deal gives Novacap a U.S. footprint and strengthens its global pharmaceutical synthesis and commercial manufacturing capabilities.

ANI Pharmaceuticals Acquires Four ANDAs from Oakrum Pharma, LLC

July 28, 2022

Pharmaceuticals

ANI Pharmaceuticals, Inc. acquired four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC in an asset purchase announced July 28, 2022. The acquisition expands ANI's generics product portfolio and is intended to enable product launches and revenue contribution beginning in 2023.

Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion

February 11, 2025

Biotechnology

Novartis has completed the acquisition of Anthos Therapeutics, a Blackstone Life Sciences–backed clinical-stage biopharmaceutical company, in a deal valued at up to $3.1 billion, including $925 million paid upfront. The acquisition gives Novartis ownership of abelacimab, a Phase 3 factor XI inhibitor being developed to prevent stroke and cancer-associated thrombosis, with remaining milestone payments contingent on regulatory and commercial outcomes.

Novo Holdings Acquires Catalent for $16.5 Billion

December 18, 2024

Healthcare Services

Novo Holdings has completed its previously announced all-cash acquisition of Catalent, Inc. for an enterprise value of approximately $16.5 billion, with Catalent stockholders receiving $63.50 per share. Shortly after closing, Novo Nordisk will acquire three Catalent fill-finish sites (Anagni, Italy; Bloomington, Indiana; and Brussels, Belgium) and related assets from Novo Holdings.

Novartis Acquires Mariana Oncology

May 2, 2024

Biotechnology

Novartis will acquire Mariana Oncology for $1 billion upfront and up to $750 million in milestone payments, bringing Mariana's peptide-based radiopharmaceutical pipeline and manufacturing capabilities into Novartis. The deal adds radioligand therapeutic discovery, isotope supply chain and manufacturing know-how to Novartis to accelerate development and commercialization of targeted cancer therapies.

Novo Integrated Sciences / Novo Healthnet Acquire Acenzia Inc.

June 29, 2021

Pharmaceuticals

Novo Integrated Sciences, through its wholly owned subsidiary Novo Healthnet Limited, completed the acquisition of Acenzia Inc., a Windsor, Ontario-based nutraceutical manufacturer and diagnostics developer. The all-share transaction closed on June 24, 2021 and is valued at $14,884,039; Novo said the purchase will give it direct control of development, manufacturing and distribution of wellness products and personalized diagnostics.